Clinical Trial Detail

NCT ID NCT02624570
Title Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy.
Recruitment No longer available
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

acute myeloid leukemia

Therapies

Midostaurin

Age Groups: adult

Additional content available in CKB BOOST